BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can be used for multiple mutant-EGFR-driven non-small cell lung cancer (NSCLC) research[1].
Molecular Weight:
516.59
CAS Number:
[2050906-40-4]
Formula:
C27H32N8O3
Target:
EGFR
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted